MCID: PLM014
MIFTS: 49

Pleomorphic Adenoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Pleomorphic Adenoma

MalaCards integrated aliases for Pleomorphic Adenoma:

Name: Pleomorphic Adenoma 12 15
Mixed Tumor, Not Otherwise Specified 73
Mixed Tumor of the Salivary Gland 12
Mixed Salivary Gland Tumor 73
Adenoma, Pleomorphic 44
Adenoma Pleomorphic 55

Classifications:



External Ids:

Disease Ontology 12 DOID:452
MeSH 44 D008949
NCIt 50 C35691 C8602
SNOMED-CT 68 8360001

Summaries for Pleomorphic Adenoma

Disease Ontology : 12 A gastrointestinal benign neoplasm that is a located in the salivary glands.

MalaCards based summary : Pleomorphic Adenoma, also known as mixed tumor, not otherwise specified, is related to pleomorphic adenoma carcinoma and salivary gland adenoma, pleomorphic. An important gene associated with Pleomorphic Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are Development EGFR signaling pathway and DNA Damage. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, trachea and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Pleomorphic adenoma is a common benign salivary gland neoplasm characterised by neoplastic proliferation... more...

Related Diseases for Pleomorphic Adenoma

Diseases related to Pleomorphic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 282)
# Related Disease Score Top Affiliating Genes
1 pleomorphic adenoma carcinoma 34.1 ERBB2 HMGA2 TP53
2 salivary gland adenoma, pleomorphic 33.0 HMGA2 PLAG1 S100B
3 adenoma 32.2 PLAG1 PLAGL1 PLAGL2 TP53
4 epithelial-myoepithelial carcinoma 30.7 HMGA2 KRT14 TP53
5 mucoepidermoid carcinoma 30.7 ERBB2 KRT14 MUC1 TP63
6 carcinosarcoma 30.5 ACTC1 ERBB2 MUC1 TP53 VIM
7 fasciitis 30.4 ACTC1 MUC1 VIM
8 neurilemmoma 30.3 GFAP S100B VIM
9 nodular hidradenoma 30.2 MUC1 VIM
10 myoepithelioma 30.2 ACTC1 GFAP KRT14 S100B SERPINB5 TP63
11 chordoma 30.2 GFAP MUC1 S100B VIM
12 spindle cell lipoma 30.1 ACTC1 MDM2 VIM
13 pleomorphic lipoma 30.0 HMGA2 MDM2
14 giant cell tumor 30.0 ACTC1 MUC1 VIM
15 in situ carcinoma 30.0 ERBB2 KRT14 TP53
16 leiomyoma 29.9 ACTC1 HMGA2 VIM
17 mesenchymoma 29.9 HMGA2 MDM2
18 myxoid liposarcoma 29.9 HMGA2 MDM2 TP53
19 syringoma 29.9 GFAP MUC1 S100B SERPINB5 TP63 VIM
20 polymorphous low-grade adenocarcinoma 29.8 ACTC1 MUC1 S100B SERPINB5 TP63 VIM
21 liposarcoma 29.8 HMGA2 MDM2 TP53 VIM
22 adenoid cystic carcinoma 29.8 ACTC1 ERBB2 KRT14 MUC1 S100B SERPINB5
23 hemangiopericytoma, malignant 29.8 ACTC1 MDM2 MUC1 S100B VIM
24 leiomyosarcoma 29.6 ACTC1 MDM2 S100B TP53 VIM
25 mixed lacrimal gland cancer 11.7
26 adenocarcinoma 10.5
27 squamous cell carcinoma 10.3
28 hard palate cancer 10.3
29 scrotal carcinoma 10.3 HMGA2 TP53
30 astroblastoma 10.3 GFAP VIM
31 central nervous system primitive neuroectodermal neoplasm 10.3 GFAP TP53
32 cerebral neuroblastoma 10.3 GFAP TP53
33 mixed glioma 10.3 GFAP TP53
34 spinal cancer 10.3 GFAP TP53
35 endometrial mucinous adenocarcinoma 10.3 MUC1 VIM
36 bile duct adenoma 10.3 MUC1 VIM
37 biphasic synovial sarcoma 10.3 MUC1 VIM
38 dysembryoplastic neuroepithelial tumor 10.3 GFAP S100B
39 uterine corpus serous adenocarcinoma 10.3 ERBB2 TP53
40 non-proliferative fibrocystic change of the breast 10.3 ERBB2 TP53
41 aggressive digital papillary adenocarcinoma 10.3 MUC1 S100B
42 frontal convexity meningioma 10.3 GFAP TP53
43 hydromyelia 10.3 S100B VIM
44 gliofibroma 10.3 GFAP TP53
45 localized hypertrophic neuropathy 10.3 MUC1 S100B
46 sclerosing perineurioma 10.3 MUC1 S100B
47 benign metastasizing leiomyoma 10.3 ACTC1 VIM
48 bednar tumor 10.3 S100B VIM
49 primitive neuroectodermal tumor of the cervix uteri 10.3 GFAP VIM
50 benign breast phyllodes tumor 10.3 TP63 VIM

Graphical network of the top 20 diseases related to Pleomorphic Adenoma:



Diseases related to Pleomorphic Adenoma

Symptoms & Phenotypes for Pleomorphic Adenoma

GenomeRNAi Phenotypes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

26 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 S100B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.84 VIM
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.84 PLAGL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.84 PLAG1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.84 PLAGL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.84 PLAGL2 VIM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.84 PLAG1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.84 ERBB2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.84 ERBB2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.84 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.84 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.84 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.84 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.84 VIM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.84 ERBB2 PLAG1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.84 PLAGL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.84 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.84 PLAG1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.84 ERBB2 PLAG1 PLAGL2 S100B VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 PLAGL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.84 PLAGL2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 ERBB2 S100B VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.84 PLAG1

MGI Mouse Phenotypes related to Pleomorphic Adenoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 ACTC1 AR ERBB2 GFAP KRT14 MDM2
2 growth/size/body region MP:0005378 10.23 ACTC1 AR ERBB2 GFAP KRT14 MDM2
3 cardiovascular system MP:0005385 10.22 ACTC1 AR ERBB2 GFAP MDM2 MYOZ2
4 homeostasis/metabolism MP:0005376 10.21 ACTC1 AR ERBB2 GFAP KRT14 MDM2
5 embryo MP:0005380 10.13 AR ERBB2 MDM2 PLAG1 PLAGL1 SERPINB5
6 mortality/aging MP:0010768 10.13 ACTC1 AR ERBB2 GFAP KRT14 MDM2
7 digestive/alimentary MP:0005381 10.1 AR ERBB2 GFAP KRT14 MDM2 PLAGL2
8 integument MP:0010771 10.01 AR ERBB2 KRT14 MDM2 PLAGL1 S100B
9 muscle MP:0005369 9.91 ACTC1 AR ERBB2 GFAP MDM2 MYOZ2
10 limbs/digits/tail MP:0005371 9.85 AR ERBB2 MDM2 PLAGL1 TP53 TP63
11 neoplasm MP:0002006 9.63 AR ERBB2 KRT14 MDM2 TP53 TP63
12 normal MP:0002873 9.61 ACTC1 AR ERBB2 GFAP MDM2 S100B
13 reproductive system MP:0005389 9.23 AR ERBB2 KRT14 MDM2 PLAG1 TP53

Drugs & Therapeutics for Pleomorphic Adenoma

Drugs for Pleomorphic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
4
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
5
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
6
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
7
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
8
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
9
Doxil Approved June 1999 Phase 2, Phase 3 31703
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
11 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
12 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
13 Alkylating Agents Phase 3,Phase 2
14 Antineoplastic Agents, Alkylating Phase 3,Phase 2
15
Isophosphamide mustard Phase 3,Phase 2 0
16 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
17
Mesna Approved, Investigational Phase 2 3375-50-6 598
18
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
19
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
20
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
21
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
22
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
23
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
24
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
25
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
26
Everolimus Approved Phase 2 159351-69-6 6442177
27
Nivolumab Approved Phase 2 946414-94-4
28
Olaparib Approved Phase 2 763113-22-0 23725625
29
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
30
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
31
Metformin Approved Phase 2 657-24-9 14219 4091
32
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
33
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751
34
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
35
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
36
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
38
Iniparib Investigational Phase 2 160003-66-7
39
Saracatinib Investigational Phase 2 379231-04-6
40
Cediranib Investigational Phase 2 288383-20-0 9933475
41
Tremelimumab Investigational Phase 2 745013-59-6
42 Antiviral Agents Phase 2
43 Immunosuppressive Agents Phase 2,Phase 1
44 Immunologic Factors Phase 2,Phase 1
45 Anti-Infective Agents Phase 2
46 Antimetabolites Phase 2,Phase 1
47 Antimetabolites, Antineoplastic Phase 2,Phase 1
48 Epothilones Phase 2,Phase 1
49 Protein Kinase Inhibitors Phase 2,Phase 1
50 Antibiotics, Antitubercular Phase 2

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Not yet recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
4 Quadrant Versus Superficial Parotidectomy Withdrawn NCT01607866 Phase 2, Phase 3
5 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
6 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
7 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
8 Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours Completed NCT00189410 Phase 2 Pegylated Liposomal Doxorubicin and Carboplatin
9 Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus Completed NCT00231842 Phase 2 Ifosfamide;Cisplatin
10 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
11 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
12 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
13 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
14 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
15 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
16 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
17 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
18 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
19 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
20 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
21 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
22 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
23 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
24 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
25 Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Recruiting NCT03458728 Phase 1, Phase 2 BAY806946
26 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
27 Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
28 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
29 Vorinostat (SAHA) in Uterine Sarcoma Recruiting NCT03509207 Phase 2 Vorinostat Oral Capsule
30 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
31 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
32 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
33 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
34 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
35 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
36 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Not yet recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
37 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
38 Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer Terminated NCT00322881 Phase 2 Paclitaxel;Carboplatin
39 Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy Terminated NCT00505492 Phase 2 Carboplatin;Cisplatin;Paclitaxel
40 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
41 Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies Withdrawn NCT00984217 Phase 2 Panitumumab
42 Suitability of DCE-MRI for Detection of Vascular Changes After VBT Unknown status NCT01991808 Phase 1
43 A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Unknown status NCT01454479 Phase 1 Lapatinib and ixempra
44 Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors Completed NCT00413322 Phase 1 belinostat;5-Fluorouracil (5-FU)
45 Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00413075 Phase 1 oral belinostat
46 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
47 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
48 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting NCT03206177 Phase 1 Galunisertib;Paclitaxel;Carboplatin
49 Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting NCT03552471 Phase 1 Rucaparib Camsylate
50 CBT-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors Recruiting NCT03053466 Phase 1 CBT-501

Search NIH Clinical Center for Pleomorphic Adenoma

Cochrane evidence based reviews: adenoma, pleomorphic

Genetic Tests for Pleomorphic Adenoma

Anatomical Context for Pleomorphic Adenoma

MalaCards organs/tissues related to Pleomorphic Adenoma:

41
Salivary Gland, Trachea, Lung, Tongue, Bone, Pituitary, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Pleomorphic Adenoma:

19
The Salivary Gl

Publications for Pleomorphic Adenoma

Articles related to Pleomorphic Adenoma:

(show top 50) (show all 1097)
# Title Authors Year
1
Primary carcinoma ex-pleomorphic adenoma of anterior commissure of the larynx. ( 29980410 )
2018
2
Cripto-1 is overexpressed in carcinoma ex pleomorphic adenoma of salivary gland. ( 29594385 )
2018
3
Lacrimal gland pleomorphic adenoma and malignant epithelial tumours: clinical and imaging differences. ( 29680804 )
2018
4
Effect of Xylosyltransferase-I Silencing on Implanting Growth of Salivary Pleomorphic Adenoma. ( 29867072 )
2018
5
A rare case of atypical pleomorphic adenoma arising from periocular ectopic lacrimal gland. ( 29936687 )
2018
6
Pleomorphic adenoma of salivary glands: common and uncommon CT and MR imaging features. ( 29845358 )
2018
7
Pleomorphic adenoma of the lacrimal gland: A review with updates on malignant transformation and molecular genetics. ( 29755265 )
2018
8
Promoter hypermethylation may contribute to Ea89cadherin repression in the human salivary carcinoma ex pleomorphic adenoma. ( 29207084 )
2018
9
Complications after superficial parotidectomy for pleomorphic adenoma. ( 29924764 )
2018
10
A huge pleomorphic adenoma of the submandibular salivary gland. ( 29549132 )
2018
11
Pleomorphic adenoma of nasal septum: a rare case. ( 29592986 )
2018
12
68Ga-DOTA-TOC Uptake in Pleomorphic Adenoma. ( 29847321 )
2018
13
Metastasizing pleomorphic adenoma in the multiple organs: A case report on FDG-PET/CT imaging. ( 29879077 )
2018
14
Carcinosarcoma ex Pleomorphic Adenoma of the Submandibular Gland in a 64-Year-Old Man: A Case Report. ( 29540647 )
2018
15
Dedifferentiated adenoid cystic carcinoma ex pleomorphic adenoma of the parotid. ( 29893347 )
2018
16
Pleomorphic Adenoma of Submandibular Gland with Extensive Cystic Keratinization. ( 29290205 )
2018
17
Recurrent rearrangements of the PLAG1 and HMGA2 genes in lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma. ( 29437290 )
2018
18
Large Pleomorphic Adenoma of Hard Palate. ( 29963438 )
2018
19
Metastasising Pleomorphic Salivary Adenoma: A Rare Case Report of a Massive Untreated Minor Salivary Gland Pleomorphic Adenoma with Concurrent Ipsilateral Cervical Node Metastases. ( 29725854 )
2018
20
Lacrimal myoepithelial carcinoma ex recurrent pleomorphic adenoma: A clinicopathological report and review of the literature. ( 29387416 )
2018
21
Gray scale and doppler ultrasonography features of the carcinoma ex pleomorphic adenoma. ( 29365290 )
2018
22
Synchronous pleomorphic adenoma and oncocytic carcinoma in the ipsilateral parotid gland. ( 29934012 )
2018
23
The Effectiveness of Sternocleidomastoid Flap Versus Superficial Musculoaponeurotic System Flap for the Prevention of Frey Syndrome and Facial Depressed Deformity in Parotid Surgery for Pleomorphic Adenoma. ( 29095193 )
2018
24
Soft Palate Pleomorphic Adenoma of a Minor Salivary Gland: An Unusual Presentation. ( 29808148 )
2018
25
Submandibular gland pleomorphic adenoma: Histopathological capsular characteristics and correlation with the surgical outcome. ( 29689463 )
2018
26
Spindle cell lipoma mimicking pleomorphic adenoma: A diagnostic challenge on cytology. ( 30468314 )
2018
27
Acantholytic Squamous Cell Carcinoma and Salivary Duct Carcinoma Ex-pleomorphic Adenoma of the Submandibular Gland: A Report of Two Extremely Rare Cases with an Immunohistochemical Analysis. ( 30484070 )
2018
28
A comparison of conventional and diffusion-weighted magnetic resonance imaging in the diagnosis of sialadenitis and pleomorphic adenoma. ( 30497909 )
2018
29
Diagnosis of an extremely rare pleomorphic adenoma of the breast with core needle biopsy: A case report. ( 30510762 )
2018
30
A rare ectopic localization of pleomorphic adenoma. ( 30513390 )
2018
31
Oncocytic cystadenoma and oncocytic cysts of the parotid gland occurring synchronously with a pleomorphic adenoma. ( 30522841 )
2018
32
Pleomorphic adenoma of the mandibular salivary gland in a captive African pygmy hedgehog (Atelerix albiventris). ( 30531130 )
2018
33
Human epithelial growth factor receptor 2 in human salivary carcinoma ex pleomorphic adenoma: a potential therapeutic target. ( 30555262 )
2018
34
CD44 expression in pleomorphic adenoma, carcinoma ex pleomorphic adenoma and their adjacent normal salivary glands. ( 30233657 )
2018
35
A rare case of pleomorphic adenoma with difficult diagnosis using biopsy. ( 30233900 )
2018
36
A rare case of pleomorphic adenoma of the breast: Ultrasonography and pathology findings. ( 30240069 )
2018
37
Squamous Metaplasia in Pleomorphic Adenoma: A Diagnostic and Prognostic Enigma. ( 30269471 )
2018
38
Primary pleomorphic adenoma of the middle ear and mastoid. ( 30273440 )
2018
39
A new ligand of CD105 screened out by phage display technology provides a reliable identification of recurrent or metastasizing pleomorphic adenoma from pleomorphic adenoma. ( 30273915 )
2018
40
Primary pulmonary pleomorphic adenoma: A rare case report. ( 30303174 )
2018
41
Clinicopathological effect of PLAG1 fusion genes in pleomorphic adenoma and carcinoma ex pleomorphic adenoma with special emphasis on histological features. ( 30307055 )
2018
42
Right main bronchial pleomorphic adenoma: A case report and literature review. ( 30334948 )
2018
43
Parapharyngeal Space Venous Malformation: An Imaging Mimic of Pleomorphic Adenoma. ( 30409847 )
2018
44
Technique of The Buccal Fat Pad Flap as an Alternative for the Surgical Defect of Pleomorphic Adenoma. ( 30418286 )
2018
45
The role of adjuvant radiotherapy in management of recurrent pleomorphic adenoma of the parotid gland: a systematic review. ( 30426229 )
2018
46
Pleomorphic adenoma of the head and neck in children: presentation and management. ( 30431646 )
2018
47
Carcinoma Ex Pleomorphic Adenoma Presented as a Gigantic Tumor: Treatment and Diagnostic Challenges. ( 30038735 )
2018
48
Pleomorphic Adenoma of the Nasolacrimal Duct. ( 30054608 )
2018
49
Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report. ( 30087853 )
2018
50
Age and adenoma size are independent risk factors for the development of carcinoma ex pleomorphic adenoma. ( 30115468 )
2018

Variations for Pleomorphic Adenoma

Cosmic variations for Pleomorphic Adenoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43909 TP53 salivary gland,parotid,adenoma,pleomorphic c.817C>A p.R273S 17:7673803-7673803 15
2 COSM10808 TP53 salivary gland,parotid,adenoma,pleomorphic c.488A>G p.Y163C 17:7675124-7675124 15
3 COSM6932 TP53 salivary gland,parotid,adenoma,myoepithelial c.733G>A p.G245S 17:7674230-7674230 11
4 COSM43635 TP53 salivary gland,parotid,adenoma,myoepithelial c.536A>T p.H179L 17:7675076-7675076 11
5 COSM13168 CTNNB1 salivary gland,parotid,adenoma,NS c.104T>C p.I35T 3:41224616-41224616 10
6 COSM5688 CTNNB1 salivary gland,parotid,adenoma,NS c.121A>C p.T41P 3:41224633-41224633 10
7 COSM21826 ATM salivary gland,parotid,adenoma,NS c.2572T>C p.F858L 11:108267276-108267276 10

Copy number variations for Pleomorphic Adenoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 239266 8 38279166 38315052 Gain FGFR1 Pleomorphic adenoma

Expression for Pleomorphic Adenoma

Search GEO for disease gene expression data for Pleomorphic Adenoma.

Pathways for Pleomorphic Adenoma

GO Terms for Pleomorphic Adenoma

Cellular components related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.97 ACTC1 AR ERBB2 GFAP KRT14 MDM2
2 nucleus GO:0005634 9.77 AR ERBB2 HMGA2 KRT14 MDM2 MUC1
3 nuclear chromatin GO:0000790 8.92 AR MUC1 TP53 TP63

Biological processes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 AR HMGA2 PLAG1 PLAGL1 PLAGL2 TP53
2 negative regulation of apoptotic process GO:0043066 9.92 ACTC1 ERBB2 HMGA2 MDM2 TP53
3 transcription by RNA polymerase II GO:0006366 9.8 HMGA2 PLAG1 PLAGL1 PLAGL2 TP53 TP63
4 cell proliferation GO:0008283 9.77 AR ERBB2 S100B TP53 TP63
5 cellular response to hypoxia GO:0071456 9.76 MDM2 S100B TP53
6 regulation of signal transduction by p53 class mediator GO:1901796 9.67 MDM2 TP53 TP63
7 negative regulation of neuron projection development GO:0010977 9.63 GFAP MDM2 VIM
8 intermediate filament organization GO:0045109 9.58 GFAP VIM
9 astrocyte development GO:0014002 9.57 GFAP VIM
10 positive regulation of glial cell proliferation GO:0060252 9.56 GFAP PLAG1
11 prostate gland development GO:0030850 9.55 AR TP63
12 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.54 MUC1 TP53
13 positive regulation of transcription by RNA polymerase III GO:0045945 9.51 AR ERBB2
14 Bergmann glial cell differentiation GO:0060020 9.48 GFAP VIM
15 prostate gland growth GO:0060736 9.43 AR PLAG1
16 cellular response to actinomycin D GO:0072717 9.26 MDM2 TP53
17 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.26 MDM2 MUC1 PLAGL1 TP53
18 positive regulation of gene expression GO:0010628 9.23 ACTC1 AR ERBB2 HMGA2 MDM2 PLAG1
19 intermediate filament-based process GO:0045103 9.16 GFAP VIM

Molecular functions related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.95 AR HMGA2 PLAG1 PLAGL1 PLAGL2 TP53
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.72 AR HMGA2 MUC1 PLAG1 TP53
3 identical protein binding GO:0042802 9.7 ERBB2 GFAP MDM2 S100B TP53 TP63
4 transcription regulatory region DNA binding GO:0044212 9.67 AR HMGA2 TP53 TP63
5 structural constituent of cytoskeleton GO:0005200 9.61 GFAP KRT14 VIM
6 proximal promoter DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001077 9.35 AR HMGA2 PLAG1 PLAGL2 TP63
7 keratin filament binding GO:1990254 9.26 KRT14 VIM
8 p53 binding GO:0002039 8.92 MDM2 MUC1 TP53 TP63

Sources for Pleomorphic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....